Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease

Abstract Preliminary evidence suggests perturbations of the kynurenine pathway (KP) of tryptophan metabolism in infants with single ventricle heart disease (SVHD). In 72 infants with SVHD undergoing stage 2 palliation (S2P) and 41 controls, we quantified serum KP metabolite concentrations via tandem...

Full description

Saved in:
Bibliographic Details
Main Authors: Jennifer Romanowicz, Sierra Niemiec, Ludmila Khailova, Tanner Lehmann, Christopher A. Mancuso, Max B. Mitchell, Gareth J. Morgan, Mark Twite, Michael V. DiMaria, Jelena Klawitter, Jesse A. Davidson, Benjamin S. Frank
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Physiological Reports
Subjects:
Online Access:https://doi.org/10.14814/phy2.70133
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846155362244231168
author Jennifer Romanowicz
Sierra Niemiec
Ludmila Khailova
Tanner Lehmann
Christopher A. Mancuso
Max B. Mitchell
Gareth J. Morgan
Mark Twite
Michael V. DiMaria
Jelena Klawitter
Jesse A. Davidson
Benjamin S. Frank
author_facet Jennifer Romanowicz
Sierra Niemiec
Ludmila Khailova
Tanner Lehmann
Christopher A. Mancuso
Max B. Mitchell
Gareth J. Morgan
Mark Twite
Michael V. DiMaria
Jelena Klawitter
Jesse A. Davidson
Benjamin S. Frank
author_sort Jennifer Romanowicz
collection DOAJ
description Abstract Preliminary evidence suggests perturbations of the kynurenine pathway (KP) of tryptophan metabolism in infants with single ventricle heart disease (SVHD). In 72 infants with SVHD undergoing stage 2 palliation (S2P) and 41 controls, we quantified serum KP metabolite concentrations via tandem mass spectroscopy pre‐S2P and post‐S2P at 2, 24, and 48 h and assessed metabolite relationships with post‐S2P outcomes (length of stay, hypoxemia burden, and intubation duration). Pre‐S2P, SVHD infants had lower tryptophan and serotonin levels and higher kynurenic acid, 3‐hydroxykynurenine, and picolinic acid levels than controls. Post‐S2P, metabolites peaked at 2 h, with return to baseline by 48 h for all except kynurenic acid, which remained elevated. Metabolite concentrations pre‐S2P were poorly associated with outcomes. A lower serotonin peak 2 h post‐S2P was associated with longer length of stay and intubation duration. Multiple metabolites at 24 and 48 h correlated with outcomes; notably, elevated kynurenic acid was associated with worse results for all three outcomes. Our results confirm that interstage SVHD infants have altered KP activity compared to controls. Further, the link between outcomes and KP metabolites post‐S2P—but not at baseline—demonstrates that acute, perioperative changes in tryptophan catabolism may be more important to tolerating S2P physiology than chronic interstage changes.
format Article
id doaj-art-ad23c588ab7c448a8d2b3df90000df77
institution Kabale University
issn 2051-817X
language English
publishDate 2024-11-01
publisher Wiley
record_format Article
series Physiological Reports
spelling doaj-art-ad23c588ab7c448a8d2b3df90000df772024-11-26T12:02:37ZengWileyPhysiological Reports2051-817X2024-11-011222n/an/a10.14814/phy2.70133Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart diseaseJennifer Romanowicz0Sierra Niemiec1Ludmila Khailova2Tanner Lehmann3Christopher A. Mancuso4Max B. Mitchell5Gareth J. Morgan6Mark Twite7Michael V. DiMaria8Jelena Klawitter9Jesse A. Davidson10Benjamin S. Frank11Department of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Biostatistics and Informatics University of Colorado Anschutz Aurora Colorado USADepartment of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Biostatistics and Informatics University of Colorado Anschutz Aurora Colorado USADepartment of Cardiac Surgery Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Anesthesiology University of Colorado Anschutz Aurora Colorado USACongenital Heart Center University of Michigan C.S. Mott Children's Hospital Ann Arbor Michigan USADepartment of Anesthesiology University of Colorado Anschutz Aurora Colorado USADepartment of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USADepartment of Pediatrics, Section of Cardiology Children's Hospital Colorado and University of Colorado Anschutz Aurora Colorado USAAbstract Preliminary evidence suggests perturbations of the kynurenine pathway (KP) of tryptophan metabolism in infants with single ventricle heart disease (SVHD). In 72 infants with SVHD undergoing stage 2 palliation (S2P) and 41 controls, we quantified serum KP metabolite concentrations via tandem mass spectroscopy pre‐S2P and post‐S2P at 2, 24, and 48 h and assessed metabolite relationships with post‐S2P outcomes (length of stay, hypoxemia burden, and intubation duration). Pre‐S2P, SVHD infants had lower tryptophan and serotonin levels and higher kynurenic acid, 3‐hydroxykynurenine, and picolinic acid levels than controls. Post‐S2P, metabolites peaked at 2 h, with return to baseline by 48 h for all except kynurenic acid, which remained elevated. Metabolite concentrations pre‐S2P were poorly associated with outcomes. A lower serotonin peak 2 h post‐S2P was associated with longer length of stay and intubation duration. Multiple metabolites at 24 and 48 h correlated with outcomes; notably, elevated kynurenic acid was associated with worse results for all three outcomes. Our results confirm that interstage SVHD infants have altered KP activity compared to controls. Further, the link between outcomes and KP metabolites post‐S2P—but not at baseline—demonstrates that acute, perioperative changes in tryptophan catabolism may be more important to tolerating S2P physiology than chronic interstage changes.https://doi.org/10.14814/phy2.70133cardiac surgerycongenital heart diseaseGlennkynurenic acidserotonin
spellingShingle Jennifer Romanowicz
Sierra Niemiec
Ludmila Khailova
Tanner Lehmann
Christopher A. Mancuso
Max B. Mitchell
Gareth J. Morgan
Mark Twite
Michael V. DiMaria
Jelena Klawitter
Jesse A. Davidson
Benjamin S. Frank
Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
Physiological Reports
cardiac surgery
congenital heart disease
Glenn
kynurenic acid
serotonin
title Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
title_full Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
title_fullStr Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
title_full_unstemmed Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
title_short Perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
title_sort perturbations of tryptophan catabolism via the kynurenine pathway are associated with stage 2 postoperative outcomes in single ventricle heart disease
topic cardiac surgery
congenital heart disease
Glenn
kynurenic acid
serotonin
url https://doi.org/10.14814/phy2.70133
work_keys_str_mv AT jenniferromanowicz perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT sierraniemiec perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT ludmilakhailova perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT tannerlehmann perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT christopheramancuso perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT maxbmitchell perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT garethjmorgan perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT marktwite perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT michaelvdimaria perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT jelenaklawitter perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT jesseadavidson perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease
AT benjaminsfrank perturbationsoftryptophancatabolismviathekynureninepathwayareassociatedwithstage2postoperativeoutcomesinsingleventricleheartdisease